• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 Bliss 定义的药物独立性,通过统计学方法确定协同作用。

Statistical determination of synergy based on Bliss definition of drugs independence.

机构信息

Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.

Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.

出版信息

PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.

DOI:10.1371/journal.pone.0224137
PMID:31765385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6876842/
Abstract

Although synergy is a pillar of modern pharmacology, toxicology, and medicine, there is no consensus on its definition despite its nearly one hundred-year history. Moreover, methods for statistical determination of synergy that account for variation of response to treatment are underdeveloped and if exist are reduced to the traditional t-test, but do not comply with the normal distribution assumption. We offer statistical models for estimation of synergy using an established definition of Bliss drugs' independence. Although Bliss definition is well-known, it remains a theoretical concept and has never been applied for statistical determination of synergy with various forms of treatment outcome. We rigorously and consistently extend the Bliss definition to detect statistically significant synergy under various designs: (1) in vitro, when the outcome of a cell culture experiment with replicates is the proportion of surviving cells for a single dose or multiple doses, (2) dose-response methodology, (3) in vivo studies in organisms, when the outcome is a longitudinal measurement such as tumor volume, and (4) clinical studies, when the outcome of treatment is measured by survival. For each design, we developed a specific statistical model and demonstrated how to test for independence, synergy, and antagonism, and compute the associated p-value.

摘要

虽然协同作用是现代药理学、毒理学和医学的一个重要支柱,但尽管其已有近百年的历史,却没有关于其定义的共识。此外,用于统计确定协同作用的方法,这些方法考虑了对治疗反应的变化,还不够发达,如果存在的话,也只是简化为传统的 t 检验,但不符合正态分布假设。我们提供了使用已建立的 Bliss 药物独立性定义来估计协同作用的统计模型。虽然 Bliss 定义是众所周知的,但它仍然是一个理论概念,从未应用于各种形式的治疗结果的协同作用的统计确定。我们严格而一致地扩展 Bliss 定义,以在各种设计下检测统计学上显著的协同作用:(1)在体外,当细胞培养实验的结果是单一剂量或多种剂量下存活细胞的比例时,(2)剂量反应方法,(3)在生物体的体内研究中,当结果是纵向测量(如肿瘤体积)时,以及(4)在临床试验中,当治疗结果通过生存来衡量时。对于每种设计,我们都开发了一个特定的统计模型,并演示了如何测试独立性、协同作用和拮抗作用,并计算了相关的 p 值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/1a0cce8a02df/pone.0224137.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/ed92eecd8a71/pone.0224137.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/e9d4afce64f5/pone.0224137.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/775ae2619129/pone.0224137.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/ef81cde037e8/pone.0224137.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/81af38cf15ec/pone.0224137.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/a452c519b38b/pone.0224137.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/a1e94979a541/pone.0224137.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/296f3fb485e4/pone.0224137.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/1a0cce8a02df/pone.0224137.g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/ed92eecd8a71/pone.0224137.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/e9d4afce64f5/pone.0224137.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/775ae2619129/pone.0224137.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/ef81cde037e8/pone.0224137.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/81af38cf15ec/pone.0224137.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/a452c519b38b/pone.0224137.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/a1e94979a541/pone.0224137.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/296f3fb485e4/pone.0224137.g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ab2/6876842/1a0cce8a02df/pone.0224137.g009.jpg

相似文献

1
Statistical determination of synergy based on Bliss definition of drugs independence.基于 Bliss 定义的药物独立性,通过统计学方法确定协同作用。
PLoS One. 2019 Nov 25;14(11):e0224137. doi: 10.1371/journal.pone.0224137. eCollection 2019.
2
Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.大规模稀疏药物组合数据集的协同作用的统计评估和可视化。
BMC Bioinformatics. 2019 Feb 18;20(1):83. doi: 10.1186/s12859-019-2642-7.
3
Statistical Assessment of Drug Synergy from In Vivo Combination Studies Using Mouse Tumor Models.利用小鼠肿瘤模型进行体内联合研究的药物协同作用的统计评估。
Cancer Res Commun. 2023 Oct 23;3(10):2146-2157. doi: 10.1158/2767-9764.CRC-23-0243.
4
A pragmatic definition of therapeutic synergy suitable for clinically relevant in vitro multicompound analyses.适用于临床相关体外多化合物分析的治疗协同作用的实用定义。
Mol Cancer Ther. 2014 Jul;13(7):1964-76. doi: 10.1158/1535-7163.MCT-13-0430. Epub 2014 Apr 22.
5
Independent drug action and its statistical implications for development of combination therapies.独立药物作用及其对联合治疗开发的统计学意义。
Contemp Clin Trials. 2020 Nov;98:106126. doi: 10.1016/j.cct.2020.106126. Epub 2020 Aug 24.
6
A New Bliss Independence Model to Analyze Drug Combination Data.一种用于分析药物组合数据的新型布利斯独立性模型。
J Biomol Screen. 2014 Jun;19(5):817-21. doi: 10.1177/1087057114521867. Epub 2014 Feb 3.
7
What is synergy? The Saariselkä agreement revisited.什么是协同作用?重新审视萨利色尔卡协议。
Front Pharmacol. 2015 Sep 1;6:181. doi: 10.3389/fphar.2015.00181. eCollection 2015.
8
Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials.从临床试验的汇总分析推断抗癌药物的协同/拮抗作用。
BMC Med Res Methodol. 2013 Jun 12;13:77. doi: 10.1186/1471-2288-13-77.
9
Detecting bliss synergy in in vivo combination studies with a tumor kinetic model.利用肿瘤动力学模型在体内联合研究中检测协同增效作用。
Pharm Stat. 2019 Nov;18(6):688-699. doi: 10.1002/pst.1952. Epub 2019 May 29.
10
Interaction index and different methods for determining drug interaction in combination therapy.联合治疗中相互作用指数及确定药物相互作用的不同方法。
J Biopharm Stat. 2007;17(3):461-80. doi: 10.1080/10543400701199593.

引用本文的文献

1
Synergistic anticancer effect of CDRI-08 and abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway.CDRI-08与醋酸阿比特龙针对PI3K/Akt通路对去势抵抗性前列腺癌的协同抗癌作用。
Iran J Basic Med Sci. 2025;28(9):1163-1170. doi: 10.22038/ijbms.2025.85330.18441.
2
CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunity.CD45隔离降低淋巴细胞中的信号阈值并增强抗肿瘤免疫力。
bioRxiv. 2025 Aug 1:2025.07.29.667400. doi: 10.1101/2025.07.29.667400.
3
MD-Syn: synergistic drug combination prediction based on a multidimensional feature fusion method and attention mechanisms.

本文引用的文献

1
Evaluation of drug combination effect using a Bliss independence dose-response surface model.使用布利斯独立剂量反应表面模型评估药物联合效应。
Stat Biopharm Res. 2018;10(2):112-122. doi: 10.1080/19466315.2018.1437071. Epub 2018 Feb 13.
2
Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.加性剂量反应模型:显式公式与洛伊相加性一致性条件
Front Pharmacol. 2018 Feb 6;9:31. doi: 10.3389/fphar.2018.00031. eCollection 2018.
3
Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
MD-Syn:基于多维特征融合方法和注意力机制的协同药物组合预测
Front Pharmacol. 2025 Jul 14;16:1564339. doi: 10.3389/fphar.2025.1564339. eCollection 2025.
4
Combination of PSMA targeting alpha-emitting radioligand [Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.在体外前列腺癌模型中,将靶向PSMA的发射α粒子放射性配体[铅]Pb-AB001与BET溴结构域抑制剂联合使用。
Med Oncol. 2025 Jul 22;42(8):362. doi: 10.1007/s12032-025-02925-9.
5
Cyclin D1 overexpression induces replication stress and microhomology-mediated end-joining dependence in mantle cell lymphoma.细胞周期蛋白D1过表达在套细胞淋巴瘤中诱导复制应激和微同源性介导的末端连接依赖性。
J Clin Invest. 2025 Jul 3;135(17). doi: 10.1172/JCI193006. eCollection 2025 Sep 2.
6
Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect.低剂量放疗可增强程序性死亡受体 1 配体(PD-L1)阻断疗法的疗效并诱导远隔效应。
J Immunother Cancer. 2025 Jun 30;13(6):e011487. doi: 10.1136/jitc-2025-011487.
7
Synergistic Effects of 2-Deoxyglucose and Diclofenac Sodium on Breast Cancer Cells: A Comparative Evaluation of MDA-231 and MCF7 Cells.2-脱氧葡萄糖与双氯芬酸钠对乳腺癌细胞的协同作用:MDA-231和MCF7细胞的比较评估
Int J Mol Sci. 2025 May 20;26(10):4894. doi: 10.3390/ijms26104894.
8
A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies.一种新型B7-H4xCD3双特异性T细胞衔接器(PF-07260437)与乳腺癌标准治疗和免疫检查点疗法协同作用。
Mol Cancer Ther. 2025 Jul 2;24(7):976-992. doi: 10.1158/1535-7163.MCT-24-0379.
9
Targeting ATF5, CEBPB, and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity.使用细胞穿透性Dpep靶向ATF5、CEBPB和CEBPD可使肿瘤细胞对NK-92MI细胞的细胞毒性敏感。
Cells. 2025 May 2;14(9):667. doi: 10.3390/cells14090667.
10
A novel role of exostosin glycosyltransferase 2 (EXT2) in glioblastoma cell metabolism, radiosensitivity and ferroptosis.外生骨疣糖基转移酶2(EXT2)在胶质母细胞瘤细胞代谢、放射敏感性和铁死亡中的新作用。
Cell Death Differ. 2025 Apr 15. doi: 10.1038/s41418-025-01503-w.
对人类结肠癌细胞系中临床相关药物组合进行的 Bliss 和 Loewe 相互作用分析揭示了协同和拮抗的复杂模式。
Oncotarget. 2017 Oct 19;8(61):103952-103967. doi: 10.18632/oncotarget.21895. eCollection 2017 Nov 28.
4
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.联合癌症疗法可通过患者间的个体差异产生疗效,而无需药物相加作用或协同作用。
Cell. 2017 Dec 14;171(7):1678-1691.e13. doi: 10.1016/j.cell.2017.11.009.
5
CImbinator: a web-based tool for drug synergy analysis in small- and large-scale datasets.CImbinator:一个基于网络的工具,用于在小规模和大规模数据集中药物协同作用的分析。
Bioinformatics. 2017 Aug 1;33(15):2410-2412. doi: 10.1093/bioinformatics/btx161.
6
Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.对Rac GTP酶抑制的治疗敏感性需要在乳腺癌中相应抑制mTORC1、AKT和MEK信号通路。
Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.
7
Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER Breast Cancer.在PTEN缺陷型雌激素受体阳性乳腺癌中,持续的治疗效果需要同时抑制磷脂酰肌醇3激酶的p110α和p110β亚型。
Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.
8
Single toxin dose-response models revisited.重新审视单一毒素剂量反应模型。
Toxicol Appl Pharmacol. 2017 Jan 1;314:12-23. doi: 10.1016/j.taap.2016.11.002. Epub 2016 Nov 12.
9
The -Value You Can't Buy.你买不到的价值。
Am Stat. 2016 Jan 2;70(1):33-38. doi: 10.1080/00031305.2015.1069760. Epub 2016 Mar 31.
10
Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma.骨肉瘤协同、临床可行联合治疗方案的鉴定
Sci Rep. 2015 Nov 25;5:16991. doi: 10.1038/srep16991.